Journal

A startup ranking is not a clinical benchmark. Here is how doctors and procurement teams can evaluate Tandem and other AI tools against the tasks that actually matter.

Tandem's integrations reveal a competition over clinical distribution. Connection depth, maintenance, partner dependence and exit arrangements matter more than logo counts.

Tandem's ambition extends beyond documentation. What it would take to coordinate clinical work reliably, and where specialist tools could remain important.

Four different routes to medical information: encounter context, research access, curated knowledge and reference-linked learning. What clinicians should compare.

Tandem leads Sifted's 2026 startup ranking. What that reveals about vertical AI businesses, and what it does not establish about clinical performance.

Why model updates, retrieval changes and personalisation challenge one-off assessments, and what proportionate lifecycle oversight could look like.

From local safety cases to integration and review burden, the practical work that separates a recognised medical device from a dependable NHS deployment.

Clinical AI value can come from evidence, workflow and implementation rather than model ownership alone. What Tandem and specialist platforms reveal about the opportunity.

Reduced regulatory duplication does not guarantee lower NHS prices. How to analyse competition, implementation costs and the value of time saved by clinical AI.

How to compare intended purpose, classification, evidence, market access and lifecycle costs after the UK decision on indefinite CE recognition.

Indefinite CE recognition reduces duplication but raises a harder question: where should Britain exercise independent judgement over clinical AI?

European clinical AI gains market-access certainty, but the policy also benefits qualifying British and global suppliers. Who can turn recognition into adoption?